Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 8/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192884 | 0.85 | F10 (0.65) | ESR2F10 | |
| SCHEMBL14781495 | 0.85 | ESR2 (0.60) | ESR2F10NR1H2ABHD6GPR119 | |
| SCHEMBL6189777 | 0.84 | F10 (0.66) | ESR2F10NR1H2ABHD6GPR119 | |
| SCHEMBL3874222 | 0.84 | ABHD6 (0.67) | ESR2F10NR1H2ABHD6GPR119 | |
| SCHEMBL17583901 | 0.83 | ESR2 (0.61) | ESR2NR1H2ABHD6GPR119MOGAT2 | |
| SCHEMBL14781510 | 0.82 | ESR2 (0.67) | ESR2NR1H2ABHD6GPR119ACACB | |
| SCHEMBL6673187 | 0.82 | F10 (0.59) | ESR2F10NR1H2GPR119 | |
| SCHEMBL6186177 | 0.81 | F10 (0.70) | F10NR1H2 | |
| SCHEMBL27229616 | 0.80 | NR1H2 (0.55) | ESR2F10NR1H2ABHD6GPR119 | |
| SCHEMBL30970509 | 0.80 | NR1H2 (0.55) | ESR2F10NR1H2ABHD6GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | ESR2 3727/4885F10 1624/4885NR1H2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.